Roche's AI-Powered CGM Receives European Approval for Type 1 and Type 2 Diabetes
Tuesday, 9 July 2024, 14:21
Roche Secures European Approval for AI-Powered CGM in Diabetes Management
Roche has successfully obtained European approval for its AI-driven Continuous Glucose Monitoring (CGM) system for both Type 1 and Type 2 diabetes.
AI-Driven Technology for Advanced Diabetes Management
The CGM system promises advanced diabetes management through innovative AI technology, catering to a broader spectrum of diabetes patients with higher efficiency and accuracy.
Roche's commitment to revolutionize diabetes care through cutting-edge AI solutions is evident in this significant milestone.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.